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Beginning in 2002, New York City (NYC) implemented numerous policies and programs targeting cardiovascular disease (CVD) risk factors. Using death certificates, we analyzed trends in NYC-specific and US mortality rates from 1990 to 2011 for all causes, any CVD, atherosclerotic CVD (ACVD), coronary artery disease (CAD), and stroke. Joinpoint analyses quantified annual percent change (APC) and evaluated whether decreases in CVD mortality accelerated after 2002 in either NYC or the total US population. Our analyses included 1,149,217 NYC decedents. The rates of decline in mortality from all causes, any CVD, and stroke in NYC did not change after 2002. Among men, the decline in ACVD mortality accelerated during 2002-2011 (APC = −4.8%, 95% confidence interval (CI): −6.1, −3.4) relative to 1990-2001 (APC = −2.3%, 95% CI: −3.1, −1.5). Among women, ACVD rates began declining more rapidly in 1993 (APC = −3.2%, 95% CI: −3.8, −2.7) and again in 2006 (APC = −6.6%, 95% CI: −8.9, −4.3) as compared with 1990-1992 (APC = 1.6%, 95% CI: −2.7, 6.0). In the US population, no acceleration of mortality decline was observed in either ACVD or CAD mortality rates after 2002. Relative to 1990-2001, atherosclerotic CVD and CAD rates began to decline more rapidly during the 2002-2011 period in both men and women-a pattern not observed in the total US population, suggesting that NYC initiatives might have had a measurable influence on delaying or reducing ACVD mortality. cardiovascular disease; chronic disease; health policy; health promotion; mortality; vital statistics Abbreviations: APC, annual percent change; CAD, coronary artery disease; CVD, cardiovascular disease; DOHMH, Department of Health and Mental Hygiene; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision; NYC, New York City.
Despite declining secular trends in cardiovascular disease (CVD) over the last half century (1), coronary heart disease and stroke continue to be leading causes of death in the United States and globally (2) , and in most areas of the world the absolute burden of CVD continues to increase (3) . These facts remain despite substantial advances in our understanding of CVD risk factors and the ability to effectively implement primary and secondary prevention programs targeting risk factor reduction, particularly among high-risk populations (4) .
To build on these successes and further reduce CVD burden, a number of municipalities have attempted to implement public health policies that can more broadly target CVD risk factors at the population level. New York City (NYC) has aggressively pursued the design and implementation of prevention-oriented public health policies and programs (5, 6) . Specifically, NYC local government has used an aggressive combination of taxation, regulation, marketing, and infrastructure investment to encourage healthier lifestyles and behaviors among residents (7) .
While numerous policies have been enacted since 2002, two broad categories of behaviorally targeted policy initiatives are illustrative. First, in 2002, a comprehensive tobacco control program was implemented which required smoke-free workplaces, increased the tax on cigarettes and the presence of antitobacco advertising, and offered free nicotine replacement therapy to smokers (8, 9) . After the introduction of this program, selfreported smoking prevalence decreased 15% between 2002 and 2004 (7) and self-reported secondhand smoke exposure declined by 23% (8) . Studies have shown high compliance by hospitality venues and reductions in salivary cotinine levels and signs/ symptoms of tobacco exposure among hospitality workers (10) . Accordingly, there is evidence that numbers of hospital admissions for acute myocardial infarction have decreased (11) , which is consistent with evaluations of similar smoke-free policies elsewhere (12, 13) . Many of these studies evaluated short-term hospitalization rates immediately following bans on indoor smoking, while the long-term trends in mortality rates remain less clear. While declines in hospitalization are encouraging, currently available evidence indicates that observed reductions in hospitalization rates have not translated into state-level declines in CVD mortality rates (14) .
Second, in an effort to promote healthy eating behaviors and improve diet quality, NYC implemented health policies aiming to discourage purchasing of fast food and increase the accessibility of nutritious foods (15, 16) . By 2008, a 2006 NYC Board of Health initiative to remove artificial trans fats from restaurant food was in full effect. Preliminary evaluations indicate that restaurant usage of trans fats has decreased from 50% to less than 2% (17) and purchases of food with 0 g of trans fat have increased from 32% to 59% (18) . Also in 2008, NYC became the first city to enact mandatory calorie labeling in restaurant chains (19) . Studies evaluating changes in consumer behavior patterns in response to calorie labeling have not found significant favorable differences (15, 16) , but some have suggested changes to industry practices, such as offering lower-calorie menu items (20) . However, these studies were limited in their cross-sectional design, small sample sizes, and short study periods, highlighting the need for long-term analyses of the collective impact of these and other NYC health initiatives.
Using death certificate data from the years 1990-2011, we analyzed the trajectories of CVD mortality and all-cause mortality. We focused on CVD mortality because existing evidence suggests that public health policies targeting tobacco exposure and dietary quality can impact CVD rates with relatively short lag time. All-cause mortality is of interest to understand whether an alteration in the leading cause of death will also translate into increased life expectancy.
METHODS

Data sources
NYC and US death certificate data. Death counts were derived from NYC death certificates for the years 1990-2011. The NYC health code requires complete reporting of all deaths that occur in NYC (21) . US mortality rates were obtained from the Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (WONDER) system (22).
Death certificates contain decedent information as well as the circumstances and causes of death (23) . The primary element of interest from the death certificate for this study was underlying cause of death, defined by the World Health Organization as the disease or injury that initiated the chain of events leading directly to death, or the circumstances of the accident or violence which produced the fatal injury (24) .
Underlying causes of death for deaths that occurred between 1990 and 1998 were coded using the International Classification of Diseases, Ninth Revision (ICD-9), and the International Classification of Diseases, Tenth Revision (ICD-10) was used for deaths occurring from 1999 to 2011. We utilized an ICD-9/ ICD-10 crosswalk to identify corresponding codes, ensuring that causes of death were matched with a high comparability ratio (25) . The 6 major outcomes we examined were mortality from all causes, any CVD, atherosclerotic CVD, coronary artery disease (CAD), ischemic stroke, and hemorrhagic stroke. We also analyzed trends for brain cancer as an internal control, because brain cancer is without known risk factors and is therefore considered to have low preventability (26) and would not be expected to be influenced by NYC health policy initiatives. ICD-9 and ICD-10 definitions for all outcomes are listed in Appendix Table 1 .
US census data and standardization of mortality rates. US intercensal estimates were used to derive NYC population denominators for each year of the study period. Age-and sexadjusted rates (numbers of deaths per 100,000 population) were computed by means of the direct method using the 2000 US standard population.
Statistical analysis
We modeled trends in mortality rates from 1990 to 2011 and determined whether significant declines occurred in response to policy initiatives implemented beginning in 2002. We selected a study period of 1990-2011 centering around the "intervention" initiation in order to capture both a sufficient baseline trend from 1990 to 2001 and a response period from 2002 to 2011. The date of intervention was also selected to coincide with the beginning of a mayoral term marked by a large number of public-healthcentered policy proposals and enactments.
Using mortality data to derive numbers of deaths and NYC population estimates as population denominators, we calculated mean and median ages at death and age-and sex-adjusted mortality rates per 100,000 population from all causes, any CVD, atherosclerotic CVD, CAD, ischemic stroke, hemorrhagic stroke, and brain/central nervous system cancers for each year in the study period. Event counts and rates were produced using SAS 9.2 (SAS Institute, Inc., Cary, North Carolina).
We employed joinpoint regression, using the National Cancer Institute's Joinpoint Regression Program (version 4.0.4) (27) , to analyze whether mortality rate trends changed significantly during the study period. Joinpoint regression uses a stepwise algorithm that tests whether a multisegmented line is a significantly better fit than a straight or less segmented line and utilizes a Monte Carlo permutation method to produce a line of best fit for each trend segment (27, 28) . Multisegmented lines indicate one or more statistically significant (P < 0.05) changes in trend during the study period, demarcated by a "joinpoint." Annual percent change (APC) was calculated as the slope of each line segment and reflects the rate of change within a specified time interval.
In examining mortality rate trends for CVD, we considered the potential influence of a change in cause-of-death reporting practice that may have occurred in response to NYC Department of Health and Mental Hygiene (DOHMH) quality improvement training. In 2009, the NYC DOHMH intervened at 8 NYC hospitals suspected to be overreporting mortality from heart disease and conducted training on proper cause-of-death documentation (29, 30) . After training, reported proportions of heart disease deaths at these hospitals fell from 68.8% in 2008 to 32.4% in 2010 (29) , and improved agreement between death certificates and hospital discharge records suggests that the accuracy of reports increased (31) . To ensure that apparent declines in CVD mortality that may have occurred after 2009 were not solely attributable to declines in overreporting, we excluded deaths occurring at quality improvement hospitals (9.2% of all NYC resident deaths) from our main analysis.
RESULTS
Characteristics of NYC resident deaths in 1990-2011
Between 1990 and 2011, a total of 1,149,217 deaths occurred in NYC among residents (after excluding quality improvement hospitals). The mean age at death for NYC residents increased from 65.6 years in 1990 to 72.5 years in 2011. For males, mean age at death was 60.9 years in 1990 and 68.4 years in 2011, and for females, mean age at death was 70.7 years in 1990 and 76.4 years in 2011. The total all-cause age-adjusted mortality rate was 895.2 deaths per 100,000 population in 1990 and 511.9 deaths per 100,000 in 2011, representing a 42.8% decline. Among males, the age-adjusted all-cause mortality rate was 1,171.6 per 100,000 in 1990 and 620.2 per 100,000 in 2011 (a 47.1% decline), and among females, all-cause mortality was 696.9 per 100,000 in 1990 and 430.9 per 100,000 in 2011 (a 38.2% decline) ( Table 1) .
The proportion of all deaths due to any CVD decreased from 43.4% in 1990 to 39.0% in 2011. Atherosclerotic CVD contributed to 31.9% of deaths in 1990 and 28.6% of deaths in 2011, and CAD contributed to 29.3% of deaths in 1990 and 26.4% of deaths in 2011. Ischemic stroke contributed to 2.6% of deaths in 1990 and 2.2% of deaths in 2011, and hemorrhagic stroke contributed to 1.1% of deaths in both 1990 and 2011. Causespecific mortality rates are presented in Table 1 and demonstrate declines in all age-and sex-adjusted CVD mortality rates during 1990-2011. 
Joinpoint regression results
All-cause mortality. Between 1990 and 2011, three distinct line segments were used to describe the observed decline in allcause mortality (Figure 1) . Overall mortality declined, with APCs of −0.6% between 1990 and 1993, −4.8% between 1994 and 1997, and −2.6% between 1998 and 2011, and there was no evidence that the rate of decline for all-cause mortality rates changed after 2002. Sex-specific trends in mortality rates were similar to overall trends (Figure 1 ), although steeper declines were observed among men, particularly from 1994 to 1997, and much of this decline was due to reductions in deaths from human immunodeficiency virus/acquired immunodeficiency syndrome among males aged 35-44 years (data not shown).
Any CVD. Overall CVD mortality rates increased in women and men by 1.5% and 0.5%, respectively, from 1990 to 1992. CVD mortality rates began to decline in 1993, with APCs of −3.7% and −3.8% in women and men, respectively, between 1993 and 2011 ( Figure 2A) . Brain/central nervous system cancers. Trends in mortality from brain and central nervous system cancers showed a constant rate of decline throughout the study period. The APC was −0.6% for males and −1.0% for females ( Figure 2F ).
Influence of NYC DOHMH intervention hospitals
Results from joinpoint regression analyses that included all NYC deaths (i.e., including cause-of-death quality improvement hospitals) are presented in Web Tables 1 and 2 (available at https://academic.oup.com/aje) and were quite similar to the aforementioned results for atherosclerotic CVD, CAD, and ischemic and hemorrhagic stroke. The pattern of results was also unchanged in corresponding sex-specific analyses. In contrast, when all hospitals were included, the results for overall CVD mortality rates demonstrated a change in mortality rate trends beginning in 2008, the year in which NYC DOHMH cause-of-death training activities were implemented (Web Figure 1) .
Joinpoint results for all-cause and CVD-specific mortality rates in the total US population between 1990 and 2011 are summarized in Web Figures 2 and 3 
DISCUSSION
We examined trends in NYC mortality rates between 1990 and 2011 to assess whether there was evidence for changes in rates of mortality from all causes and CVDs targeted by the aggressive multisectoral health policy initiatives NYC implemented in 2002. Our models for cause-specific trends suggested that mortality from atherosclerotic CVD and CAD began to decline at an accelerated rate in 2002 for men and in 2006 for women. There was no evidence for accelerated declines in mortality from either ischemic stroke or hemorrhagic stroke, each of which accounted for only a small proportion of overall deaths. Our reference outcome of mortality from brain/central nervous system cancers remained at a low and stable rate of decline, indicating that not all causes of death shifted during the study period. Despite accelerated declines in atherosclerotic CVD and CAD in NYC, the trajectory for all-cause mortality did not change in response to policy during this period. There was no evidence of accelerated decline in atherosclerotic CVD mortality in the US population during 2002-2011, suggesting that the accelerated declines in NYC were not reflecting concurrent trends at a national level.
An important strength of the current study was the use of comprehensive death certificate data which included all deaths among NYC residents that occurred in NYC during 1990-2011. (Although the 9.2% of deaths occurring at quality improvement hospitals were excluded from the main analyses, sensitivity analyses included data from all hospitals.) The joinpoint regression allowed us to systematically analyze trends in a piecewise manner, compare recent and historical trends over an extended time interval, and identify statistically significant changes in the trajectory of mortality rate trends. It is important to consider that the environmental and social changes responsible for the steep declines in mortality during the preintervention period, particularly between 1995 and 1998, may also have contributed to the declines we observed between 2002 and 2011. Analysis of the isolated time period postintervention without a baseline would fail to consider these historical reductions in mortality and might inappropriately attribute declines in mortality to recent NYC health policy initiatives rather than to a continuation of long-term secular trends. A significant shift in the trajectory of a mortality rate trend postintervention within a biologically plausible time frame offers insight on the potential for health policy to improve public health. Nevertheless, we do not know what the mortality rate trends would have looked like without policy intervention. While we assumed that historical declines would have continued at the same rates, it is also plausible that mortality rates would have accelerated without a concerted push for health in all policies. The incorporation of secular trends in US CVD mortality rates provides some perspective on this potential by demonstrating that the national trends in atherosclerotic CVD mortality rates did not show an equivalent shift between 2002 and 2011. Table 1 .
Some important limitations of our study should be noted. Changes in the quality of death certificate data over time may have contributed to the observed mortality rate trends. However, the NYC DOHMH conducted robust quality assurance cause-ofdeath training in 2009-the agency's largest and most concerted cause-of-death training initiative for which measurable outcomes have been produced (29) (30) (31) . This initiative enabled us to conduct analyses excluding hospitals that participated in the initiative to minimize bias generated by changes in cause-of-death determination over time. These data did not include records of deaths that occurred among NYC residents outside of NYC. This would only have biased the results if NYC residents were more likely to leave NYC after development of CVD and prior to death in a time-dependent fashion (i.e., with greater frequency after 2002)-which, even if it occurred, seems unlikely to have created meaningful bias in a data set of more than 1,000,000 deaths.
Despite our extended study period, it is possible that not enough time has elapsed to fully evaluate the association between NYC health policy initiatives and mortality, especially for chronic disease outcomes with longer latency periods following the focal risk factors (e.g., lung cancer following reduced tobacco exposure). However, prior research on the influence of smoke-free policy has demonstrated reductions in myocardial infarction hospital admissions (12) and mortality rates (14) during the first year following policy implementation, supporting our observation that over 10 years atherosclerotic CVD mortality rates declined, among men, beginning in the year of smoke-free legislation. In contrast, we did not observe changes in the decline of ischemic stroke mortality, which is surprising given that declines in CAD mortality were observed and these outcomes share many risk factors. This could be due to the possibility that smoke-free legislation influences smoking rates differentially by age group, favoring less decline among older persons in whom stroke risk is higher. Previous studies have shown the decline in absolute levels of smoking prevalence between 2002 and 2003 to be greater among persons aged 25-44 years (37,000 fewer smokers) or 45-64 years (32,000 fewer smokers) versus those aged ≥65 years (2,000 fewer smokers), although the relative reduction in prevalence was similar by age group (9). Moreover, it is possible that smoke-free workplaces differentially influence younger people and older people, more of whom might be retired or working in other settings, favoring reductions in CAD mortality versus stroke mortality.
Our study design could not explicitly link specific policies to changes in specific causes of death, but it could characterize mortality rates during a policy-intense time period relevant to building toward causal inference. Yet, factors unrelated to the prevention policy environment might have led to the observed changes. For example, changing socioeconomic conditions, improvements in treatments and clinical care standards, and/or improvements in access to health care all might have had an influence on mortality rates. To our knowledge, there were no systematic, abrupt citywide changes in these domains that took place during the study period in a way that would explain our observed results (including sex differences in timing). Importantly, if socioeconomic dynamics and/or access to care were to explain accelerated declines in atherosclerotic CVD, it would be expected that similar declines in all-cause mortality might also have been observed, but they were not.
Finally, these results did not arise from a randomized controlled study design, as the question under study was not amenable to an experimental design of this nature. Nevertheless, our analytical approach can account for the historical context, in which trends in CVD mortality rates were already declining in NYC, and in doing so, the results strongly suggest that these declines were accelerated subsequent to the development of an aggressive public health policy environment. We are unaware of any other large urban municipalities in which a natural experiment of this magnitude has been undertaken, making these data very unique in their ability to estimate the potential influence of aggressive multisectoral public health policy initiatives.
The results of this analysis suggest that NYC health policy initiatives implemented beginning in 2002 may have reduced mortality from atherosclerotic CVD and CAD among NYC residents, with possible differences in timing for men and women. Continued evaluation after more extended lag times is necessary to better understand the time scale on which allcause and CVD mortality rates might be modified as a result of aggressive public health policy, as well as the reasons for apparent sex differences. The quasi-experimental nature of the implementation of NYC's preventive public health policies provides a unique opportunity to assess the potential influence of local governmental efforts to change lifestyles and behaviors on mortality rates. This analysis and similar evaluations have the potential to establish infrastructure for future investigations and contribute to a body of literature that will inform the influence of municipal policy on CVD (and possibly other chronic disease) mortality rates. This is of high public health importance in a world where the majority of people are living in urban areas (32) and poised to benefit from health-oriented public health policy.
